期刊文献+

血小板活化因子乙酰水解酶基因多态性与缺血性脑卒中患者血小板活化和预后关系的研究 被引量:3

Relationship between platelet activating factor acetylhydrolase genetic polymorphism and platelet activation and prognosis in patients with ischemic stroke
下载PDF
导出
摘要 目的探讨血小板活化因子乙酰水解酶(PAF—AH)基因多态性与缺血性脑卒中的关系。方法应用PCR技术,分析205例缺血性脑卒中患者(脑卒中组)及114例健康体检者(对照组)的基因型。并测定血浆血小板活化因子(PAF)、α颗粒膜糖蛋白140(GMP-140)、β-血小板球蛋白(β-TG)和血小板第4因子(PF4)水平。结果脑卒中组PAF-AH基因突变率和血浆PAF、GMP-140、β—TG和PF4水平[分别为42.44%、(91.08±39.10)ng/L、(36.46±13.10)μg/L、(41.75±11.18)μg/L、(29.05±9.16)μg/L]均显著高于对照组[分别为21.05%、(64.30±18.81)ng/L、(18.27±7.68)μg/L、(30.94±8.47)μg/L、(18.75±6.06)μg/L](P<0.01)。脑卒中组基因突变者血浆PAF、GMP.140水平显著高于无基因突变者(P<0.01)。结论缺血性脑卒中患者急性期血小板活化增强,且与PAF。AH基因多态性相关。PAF-AH基因突变可能是缺血性脑卒中的一种遗传危险标志。 Objective To investigate the corelation between platelet activating factor acetylhydrolase (PAF-AH) genetic polymorphism and ischemic stroke. Methods The plasma PAF-AH genotype was determined in 205 patients with ischemic stroke and 114 normal subjects by the polymerase chain reaction. The levels of plasma platelet activating factor ( PAF ), platelet α -granule membrane glycoprotein- 140( GMP-140).β -thromboglobulin (β -TG) and the levels of platelet factor 4 (PF4) were analyzed. Results The prevalence of the mutation geno±pe and plasma PAF, GMP-140, β-TG and PFd in the patients with ischemic stroke [42.44%,(91.08±39.10) ng/L, (36.46 ± 13.10) μg/L, (41.75 + 11.18) lAg/L, (29.05 ± 9.16 ) μg/L, respectively ] were significantly higher than those in the controls[21.05%,(64.30 ± 18.81 ) ng/L, ( 18.27 + 7.68 ) μg/L, ( 301.94 + 8.47 ) μ g/L, ( 18.75 ± 6.06 ) μ g/L ] ( P 〈 0.01 ). The levels of plasma PAF,GMP-140 were significantly higher in mutation genotype patients than those in the normal genotype patients (P 〈0.01 ). Conclusions The activation function of platelet in the acute phase of patients with ischemic stroke increases, and it is associated with genetic polymorphism of PAF-AH. The PAF-AH gene mutation may be a novel genetic marker for high risk of ischemic stroke.
出处 《中国医师进修杂志(内科版)》 2009年第4期27-31,共5页 Chinese Journal of Postgraduates of Medicine
基金 江苏省盐城市科技计划项目(YK2004002)
关键词 脑血管意外 血小板活化 1-烷基-2-乙酰甘油磷酸胆碱酯酶 基因多态性 Cerebrovascular auident Platelet activation 1-Alkyl-2-acetylglycerophosphocholine esterase Gene polymorphism
  • 相关文献

参考文献14

  • 1Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke, 2002,33 ( 11 ) : 2570-2574.
  • 2Karasawa K, Harada A, Satoh N, et al. Plasma platelet activating factor-acetylhydrolase ( PAF-AH ). Prog Lipid Res, 2003,42 (2) : 93-114.
  • 3Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest, 1996, 97( 12 ) : 2784-2791.
  • 4芦璐,房淑欣,孙成桂.脑卒中并发深静脉血栓形成患者测定凝血、抗凝血指标的临床意义[J].中国基层医药,2005,12(9):1132-1133. 被引量:2
  • 5张颖冬.阿司匹林防治缺血性脑血管病中的阿司匹林抵抗[J].临床神经病学杂志,2005,18(3):161-163. 被引量:31
  • 6Zimmerman GA, Mcintyre TM, Prescott SM, et al. The plateletactivating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Mad,2002,30 (5 Suppl) :S294-301.
  • 7Kruse S, Mao XQ, Heinzmann A,et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet,2000,66(5): 1522-1530.
  • 8Hiramoto M, Yoshida H, lmaizumi T, et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke, 1997,28( 12):2417-2420.
  • 9张雄,袁成林,张桁忠,许俊,吴健,陈蓓蕾.血小板活化因子乙酰水解酶基因994(G→T)突变与脑梗塞的关联性[J].中华医学遗传学杂志,2005,22(4):450-452. 被引量:9
  • 10Theilmeier G, de Geest B, van Veldhoven PP, et al. HDL- associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J, 2000,14( 13 ) :2032-2039.

二级参考文献39

  • 1马英文,刘捷,樊延霞,殷延玲.脑血管病后下肢深静脉血栓形成10例临床分析[J].中国基层医药,2005,12(1):103-103. 被引量:17
  • 2吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3):162-164. 被引量:231
  • 3Zimmerman GA, McIntyre TM, Prescott SM, et al. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med,2002,30(Suppl 5):S294-301.
  • 4Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-acting factor acetylhydrolase deficiency. J Clin Invest,1996, 97:2784-2791.
  • 5Hiramoto M, Yosida H, Imaizumi T, et al. A mutation in platelet-activating factor acetylhydrolase(Val279→Phe) is a genetic risk factor for stroke. Stroke, 1997, 28:2417-2420.
  • 6Marathe GK, Zimmerman GA, Prescott SM, et al. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol,2002, 38: 193-200.
  • 7Arai H, Koizumi H, Aoki J, et al. Platelet-activating factor acetylhydrolase (PAF-AH). J Biochem,2002,131:634-640.
  • 8Quarck R, De Geest B, Stengel D, et al. Adenovirus mediated gene transfer of human platelet-activating factor acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation,1999,103: 2495-2500.
  • 9Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet,2000, 66: 1522-1530.
  • 10Chamorro A, Saiz A, Vila N, et al. Contribution of arterial blood pressure to the clinica; expression of lacunar infarction. Stroke, 1996, 27: 388-392.

共引文献39

同被引文献36

  • 1刘俊辉,刘文娴,陈立颖,李江,马琛明.不规范剂量阿司匹林对心脑血管疾病高危患者的影响[J].中国全科医学,2009,12(7):546-548. 被引量:16
  • 2张雄,袁成林,张桁忠,许俊,吴健,陈蓓蕾.血小板活化因子乙酰水解酶基因994(G→T)突变与脑梗塞的关联性[J].中华医学遗传学杂志,2005,22(4):450-452. 被引量:9
  • 3阿司匹林应用共识专家组,樊东升,高山,高旭光,贺茂林,胡学强,黄一宁,姜卫剑,李小鹰,李焰生,吕传真,潘小平,蒲传强,戚晓昆,孙宁玲,王丽娟,王少石,王拥军,张苏明,张微微,张茁,赵东.缺血性脑血管病阿司匹林规范应用共识[J].中国全科医学,2006,9(6):483-483. 被引量:4
  • 4曾拥军 陈孝东 毛成洁 等.缺血性卒中或短暂性脑缺血发作患者的卒中预防指南.国际脑血管疾病杂志,2006,14(5):325-361.
  • 5Fong J,Cheng-Ching E,Hussain MS,et al.Predictors of Biochemical Aspirin and Clopidogrel Resistance in Patients With Ischemic Stroke.J Stroke Cerebrovasc Dis,2011,20 (3):227-230.
  • 6Bousser MG,Amarenco P,Chamorro A,et al.Rationale and design of a randomized,double-blind,parallel-group study of terutroban 30mg/day versus aspirin 100mg/day in stroke patients:the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM)study.Cerebrovasc Dis,2009,27 (5):509-518.
  • 7Hermann A,Dzialowski I,Koch R,et al.Combined anti-platelet therapy with aspirin and clopidogrel:risk factor for thrombolysisrelated intracerebral hemorrhage in acute ischemic stroke?.J Neurol Sci,2009,284(1/2):155-157.
  • 8Dharmasaroja P.Aspirin non-responders in Thai ischemic stroke/TIA patients.J Med Assoc Thai,2008,91 (6):818-821.
  • 9Guthrie RM.Review of ESPS-2:prevention of secondary stroke and transient ischemic attack using aspirin and extended-release dipyridamole.Commentary.Postgrad Med,2009,121 (6):203-205.
  • 10Telman G,Kouperberg E,Sprecher E,et al.Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients.J Neurol Sci,2009,281 (1/2):2-5.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部